Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine

2 years ago

Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launchCAMBRIDGE, MA /…

Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger

2 years ago

VANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 15, 2023 / Bruush Oral Care Inc. (Nasdaq:BRSH) ("Brüush") and Arrive…

Sienna Announces December Dividend

2 years ago

MARKHAM, Ontario, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced…

Goodness Growth Holdings Announces Departure of General Counsel & Chief Compliance Officer

2 years ago

MINNEAPOLIS, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),…

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

2 years ago

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second…

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

2 years ago

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level…

Zymeworks Added to Nasdaq Biotechnology Index

2 years ago

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

CorMedix Inc. Announces Appointment of Chief Legal Officer

2 years ago

BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

Astiva Health Files Statement for Proposed Initial Public Offering

2 years ago

ORANGE, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- via IBN -- Astiva Health Inc., a fast-growing Medicare Advantage Prescription Drug (MAPD)…

Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

2 years ago

BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…